Vortioxetine (Standard)

Vortioxetine (Standard) is an analytical standard for Vortioxetine. This product is intended for research and analytical applications. Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of serotonin transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial 5-HT1B agonist (Ki: 15 nM, 33 nM) [1][2].

Product Specifications

CAS Number

[508233-74-7]

Product Name Alternative

Lu AA 21004 (Standard)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

5-HT Receptor; Reference Standards; Serotonin Transporter

Type

Reference Standards

Related Pathways

GPCR/G Protein; Neuronal Signaling; Others

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/vortioxetine-standard.html

Purity

99.28

Smiles

CC1=CC=C(SC2=CC=CC=C2N3CCNCC3)C(C)=C1

Molecular Formula

C18H22N2S

Molecular Weight

298.45

Precautions

H302, H315, H319, H335

References & Citations

[1]Bang-Andersen B, et al. Discovery of 1-[2- (2,4-dimethylphenylsulfanyl) phenyl]piperazine (Lu AA21004) : a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54 (9) :3206-21.|[2]Guilloux JP, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013 May 28;73C:147-159.|[3]Theunissen EL, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013 Jun;93 (6) :493-501.|[4]Rothschild AJ, et al. Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012 Dec;22 (12) :858-66.|[5]Mrk A, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012 Mar;340 (3) :666-75.